market research reports
0 view | +0 today
Follow
 
Scooped by rao
onto market research reports
Scoop.it!

Global Companion Diagnostic Devices Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

 

Companion diagnostics are medical devices, often an in-vitro device and provides the information that essential for safe and effective use of the corresponding drug or biotechnology product. Companion diagnostics are often developed along with drugs to aid in selecting or excluding the patient groups for the treatment with particular drug on basis of their biological characters. Companion diagnostics are developed based on biomarkers technology to predict response or severe toxicity of the drugs or biotechnological compounds. Companion diagnostics are majorly used in oncology area.

 

Some of the factors like improved efficacy and safety profiles of drugs, Accelerated drug regulatory approvals, reduced healthcare expenditure and drug development costs, increasing partnerships between market players, government organizations and other research firms over the use of co diagnostics, emergence of new pharmaceuticals and diagnostics are driving the growth of the global companion diagnostics market. However, due to the regulatory uncertainty, complex clinical trial procedures and intellectual property issues in certain areas are the few issues which are restraining the growth of the global companion diagnostics market.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-companion-diagnostic-devices-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

Global companion diagnostic tests are segmented on the basis of application, technology, end user and geographical region.

 

Based on the application, global companion diagnostic tests are segmented as:

  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Urology
  • Melanoma
  • Gastric Cancer
  • Others

 

Based on the type, global companion diagnostic tests are segmented as:

  • Screening and Detection Tests
  • Prognosis Tests
  • Theranostics Tests
  • Monitoring Tests
  • Recurrence Tests

 

Based on the end-user, global companion diagnostic tests are segmented as:

  • Hospitals
  • Diagnostic Centres
  • Others

 

To view TOC of this report is available upon request @

 https://www.precisionbusinessinsights.com/market-reports/global-companion-diagnostic-devices-market/#ulp-c654SbFYO64MsOhu

 

 

The global companion diagnostic devices market is highly fragmented due to the presence of several established large and small suppliers. The competition in the market will intensify during the forecast period as vendors adopt strategies like M&A to develop new technologies. Product approval and launch will also help to increase the volume of available diagnostic devices in the market. In addition, the vendors also work on differentiating their products based on quality, the accuracy of results, and other value added services as it will help them to gain a competitive edge over their peers.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-companion-diagnostic-devices-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, companion diagnostic devices market is segmented into five regions: North America, Europe, Latin America, Asia-Pacific and Middle East & Africa. North America expected to be major market for companion diagnostics owing to growth innovative technologies in biomarkers, increase in R&D investment in the region.  Asia-Pacific and Europe are expected to grow at a significant rate owing to large patent and consumer base, increasing government initiatives developing healthcare infrastructure, and growing disposable income.

 

Some of the players in companion diagnostic devices market are F. Hoffmann-La Roche Ltd.(Switzerland), Qiagen Ltd. (Germany), ARUP Laboratories (U.S.), Abbott Laboratories (U.S.), Biogenex Laboratories, Inc. (USA), Thermo Fisher Scientific (U.S), Ventana Medical Systems Inc. (U.S), Myriad Genetics Inc. (U.S), and Danaher (U.S) and others.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-companion-diagnostic-devices-market/

 

more...
No comment yet.
Your new post is loading...
Your new post is loading...
Scooped by rao
Scoop.it!

Global Therapeutic Vaccines Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Therapeutic vaccines are biological combinations which develop immunity against a diseased tissue or cell. Therapeutic vaccines are administered to the patient in order to induce a defence mechanism against particular disease. These are developed to treat various cancer diseases, HIV, and Alzheimer’s disease etc. Prophylactic vaccines differ from therapeutic vaccines are used for the prevention and control of diseases, while the prophylactic vaccines are only used for prevention of diseases. Therapeutic vaccines are specially manufactured for the HIV positive individuals with the healthy immune system, to increase the ability to fight against microorganisms. Therapeutic vaccines are currently developed for chronic viral infections, such as human immunodeficiency virus (HIV), human papillomavirus (HPV), herpes simplex virus (HSV), cancer, hepatitis B virus, and hepatitis C virus etc. as an alternative to antiviral treatment.

 Global Market Outline: Therapeutic Vaccines Market

 The global therapeutic vaccines market is expected to grow at a significant CAGR due to increase in the prevalence of chronic diseases such as cancer, and HIV etc. According to World Health Organisation, an escalation of the diseases such as cancer (approximately 8.8 Mn people died in 2015) and HIV expected to drive the growth of global therapeutic vaccines market over the forecasting period. The advanced and active R&D activities for therapeutic vaccines by pharmaceutical companies for various types of cancers are in pipeline which is expected to create potential opportunity in the global therapeutic vaccines market in future. Apart from this, rising number of mergers and acquisitions, and an increase in funding from government for development of therapeutic vaccines might fuel the growth of global therapeutic vaccines market over the forecasting period. However, inefficient research and development and non-existent reimbursement policies for vaccines are the primary factors which are expected to hinder the growth of global therapeutic vaccines market. Similarly, stringent regulatory implications, higher cost of vaccines, lesser accessibility to the vaccines, availability of alternative treatments for the diseases, and some adverse effects associated with the vaccines might hamper the growth of global therapeutic vaccines market over the forecast period.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-therapeutic-vaccines-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

Global therapeutic vaccines market has been segmented on the basis of product type, application, technologies, market type, and end user

 

Based on product type, global therapeutic vaccines market has been segmented into the following:

  • Conjugate vaccines
  • Live attenuated vaccines
  • Inactivated and subunit vaccines
  • Toxoid vaccines
  • Recombinant vaccines

 

Based on application, global therapeutic vaccines market has been segmented into the following:

  • Infectious Diseases
  • Oncology
  • Addiction
  • Autoimmune diseases
  • Neurological diseases
  • Others

 

Based on technology, global therapeutic vaccines market has been segmented into the following:

  • Autologous vaccines
  • Allogeneic vaccines

 

Based on the valency, global therapeutic vaccines market has been segmented into the following:

  • Monovalent vaccines
  • Multivalent vaccines

 

Based on the end-user, global therapeutic vaccines market has been segmented into the following:

  • Hospitals
  • Clinic
  • Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-therapeutic-vaccines-market/#ulp-c654SbFYO64MsOhu

 

 

The global therapeutic vaccines market is in the nascent stage where many players are actively involved in the development of therapeutic vaccines. Few companies have adopted some key business strategies, such as product innovation, and new product launching to ensure their dominance in the global therapeutic vaccines market. The global therapeutic vaccines market is positively affected by the significant rise in prevalence of chronic diseases such as cancer, and HIV etc. Few companies have taken an active lead in research and development of therapeutic vaccines. For instance, in April 2010, Dendreon Corporation, launched FDA approved immunotherapy drug Provenge, for the treatment of prostate cancer. According to U.S. Department of Health and Human Services, there are some vaccines in the clinical trial stage, such as Lucanix (Belagenpumatucel-L), gp100 melanoma vaccine, for Non-small cell lung cancer. Similarly, Merck & Co., Inc. and GSK Plc. are expected to launch vaccines such as GSK1572932A, and GV1001 having entered phase 3 trials.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-therapeutic-vaccines-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, the global therapeutic vaccines market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounts for the largest share in global therapeutic vaccines market followed by Europe and Asia-Pacific. In North-America, U.S. contributes the largest share in global therapeutic vaccines market (according to U.S. Centres for Disease Control and Prevention (CDC), therapeutic vaccines can suppress almost 10 infectious diseases in U.S. by up to 90%). Rising technology support for the development of new vaccines and well-developed healthcare infrastructure expected to fuel the growth of therapeutic vaccines market in North-America region. Europe, which currently stands at the second position in global therapeutic vaccines market, and is expected to show a significant growth due to the increase in the number of patients with chronic diseases. Asia-Pacific region expected to grow at a significant rate due to rising prevalence of various infectious and chronic diseases and aging population. Large investments in the field of research and development and increasing medical tourism in Asian countries might fuel the growth of therapeutic vaccine market in the Asia-pacific region. Latin America is another important regional market, which offers vast opportunities for the players entering into this market, and is expected to grow moderately due to the high cost of therapeutic vaccines.

 

Some of the players in global therapeutic vaccines market are Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi-Pasteur (France), Dendreon (U.S.). Agenus Inc. (U.S.), Valeant (Canada), Bavarian Nordic (Denmark), Pfizer, Inc. (U.S.) and Inovio Pharmaceuticals, Inc. (U.S.), to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-therapeutic-vaccines-market/

more...
No comment yet.
Scooped by rao
Scoop.it!

Global Hepatitis C Treatment Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Hepatitis C treatment market: Hepatitis C is an infectious disease caused by Hepatitis C virus (HCV) and affects primarily the liver. Hepatitis C is commonly caused by blood to blood contacts such as intravenous drug use, unsterilized equipment, blood transfusions, and sexual intercourse. Hepatitis C may also cause from mother to fetus during birth. People with alcoholism and HIV infection of any age group are at increased risk. Currently, there is no vaccine available to treat hepatitis C conditions. However, various drugs such as protease inhibitors, HCV polymerase inhibitors, and HCV NS5A inhibitors are commonly used to treat Hepatitis C. Early stage of infection typically has no symptoms. The critical stage of infection may display symptoms such as fever, dark urine, abdominal pain, and yellow-tinged skin occurrence. The severity in hepatitis C may lead to liver cirrhosis, liver cancer, liver failure, and sometimes also causes the dilated blood vessels in the oesophagus and stomach. Hepatitis C can be prevented by using sterilized equipment, screening of blood donors, avoiding multiple sexual partners, and avoiding sharing of injections and razors.

 Global Market Outline: Hepatitis C Treatment Market

 The global market for Hepatitis C treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis C infection. Rising awareness regarding Hepatitis C treatment, increase in healthcare expenditure, and government initiatives and various NGO’s creating awareness regarding the Hepatitis C treatment is expected to fuel the market growth over the forecast period. In addition, rise in the funding in research and development activities for Hepatitis C treatment and strong pipeline products might boost the global Hepatitis C treatment market over the forecast period. However, lack of antibiotics in the market, high cost of medications, and lack of hepatitis C infection awareness in poor countries might hamper the growth of global Hepatitis C treatment market over the forecast period.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-c-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

Hepatitis C treatment market segmented on the basis of drug class, route of administration, and distribution channel

 

Based on drug class, the hepatitis C treatment market has been segmented into the following:

  • Polymerase Inhibitors
  • NS5A Inhibitors
  • Interferons
  • HCV protease inhibitors
  • Combination Therapy

 

Based on route of administration, the hepatitis C treatment market has been segmented into the following:

  • Oral
  • Parenteral

 

Based on distribution channel, the hepatitis C treatment market has been segmented into the following:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Others

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-c-treatment-market/#ulp-c654SbFYO64MsOhu

 

 

Increase in prevalence of hepatitis C infection and liver cirrhosis expected to fuel the growth of Hepatitis C treatment market. According to the World Health Organization (WHO), globally there are 80 Mn people suffers from chronic hepatitis C virus, in that approximately 700,000 will die each year as a result of the infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their market share in global hepatitis C treatment market. For instance, in July 2011, Merck MSD, inked an agreement with Roche for the marketing approvals of Victreli (Boceprevir) triple combination therapy with peginterferon alfa and ribavirin (peg/riba). In addition, in August 2011, Vertex Pharmaceuticals Incorporated announced that Health Canada approved its Incivektm (Telaprevir) tablets for people with genotype 1 chronic hepatitis C with compensated liver disease. In January 2014, European Commission (EC) granted marketing authorization for Gilead’s Sovaldi (Sofosbuvir) to treat chronic hepatitis C infection.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-c-treatment-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, the hepatitis C treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global hepatitis C treatment market followed by Europe and Asia-Pacific. Increase in prevalence of hepatitis C infection (according to Centres for Disease Prevention and Control (CDC), approximately 2.7-3.9 Mn people in the United States are chronically infected with hepatitis C Virus), rise in the awareness among the key stakeholders towards the use of novel products and technologies to treat the hepatitis C, and increase in research and development activities are the key factors bolster the hepatitis C treatment market in North America region. Europe holds a key share in hepatitis C treatment market owing to increase in prevalence of Hepatitis C infection (according to European centre for Disease Prevention and Control approximately 5.9 Mn people are suffering from HCV infection), rise in the geriatric population, change in the lifestyle, people involving in the unprotected sexual intercourse, and increase in the research and development activities might boost the hepatitis C treatment market in Europe region. Asia-Pacific hepatitis C treatment market growth is attributed to increase in the prevalence of hepatitis C infection, rise in the population in Asia-Pacific region, and increase in the healthcare infrastructure. The Middle East & Africa region has high prevalence of HCV infection majorly in Egypt that is approximately 8434 prevalent cases per 100,000 people.

 

Some of the players in Hepatitis C treatment market are GlaxoSmithKline, plc. (U.K.), Bristol-Myers Squibb (U.S), F. Hoffmann- La Roche Ltd. (Switzerland), Merck & Co, Inc. (U.S),  Johnson & Johnson Services, Inc. (U.S.), Gilead Sciences (U.S.), AbbVie Inc. (U.S.), Vertex Pharmaceuticals Inc. (U.S.), and Kadmon Holdings, Inc. (U.S.) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-c-treatment-market/

more...
No comment yet.
Scooped by rao
Scoop.it!

Global Combination Aesthetics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Combination aesthetics therapy is also called as polytherapy that is a treatment pathway uses more than one modality The practice is not new to medicine, but is a fairly new approach in aesthetic medicine. One of the example for combination aesthetics is botulinum toxin and fillers, which is more effective when administered along with other filler than administering alone. Some of the other types of combinations are Tissue tightening plus fillers, Tissue tightening plus fractional resurfacing with carbon dioxide, cellulite remodelling with tissue tightening etc. Over recent years there has been a sharp increase in combination therapies, with many aesthetics professionals recommending combination therapies to maximise results in anti-ageing and body contouring treatments.

 

The major factors that are augmenting the growth of the market are; increase in adoption of minimally invasive and non-invasive process, growing demand of aesthetic treatment among male, rise in aging population, growing awareness of cosmetics procedures, and availability of user-friendly aesthetic devices, among others. However, high cost of treatment, low reimbursements, and risk of device malfunctions associated mostly with implants, low focus on combination aesthetics for the dermatological conditions, stringent regulation on aesthetics procedures and increase in adoption of branded beauty and cosmetics product are major factors that hamper the growth of global combination aesthetics market.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-combination-aesthetics-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

Combination aesthetics market are segmented on the basis of treatment, application, end-user and by region.

 

Based on the treatment, combination aesthetics market are segmented as:

  • Botulinum Toxin- A (BTx-A)/Dermal Filler
  • Botulinum Toxin- A (BTx-A)/Laser
  • Laser/Topical Drug
  • Laser/Radiofrequency
  • Dermal filler/Topical drug
  • Others

 

Based on the application, combination aesthetics market are segmented as:

  • Hair Removal
  • Tattoo Removal
  • Skin Resurfacing
  • Scar Removal
  • Others

 

Based on the end-user, combination aesthetics market are segmented as:

  • Hospitals
  • Ambulatory Surgical Centers
  • Dermatological Clinics

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-combination-aesthetics-market/#ulp-c654SbFYO64MsOhu

 

 

Due to intense cut-throat competition, there is a constant pressure on the players in the facial rejuvenation market to introduce newer products that is still in its nascent stage and in a constant state of flux. Due to this intense competitive pressure, there is a compulsion for early introduction of products, especially peels, topical solutions, etc. In 2014, the American Society for Aesthetic Plastic Surgery stated that about 3.5Mn botulinum toxin procedures were performed in the US. In the same year International Society of Aesthetic Plastic Surgery also reported that about 4.8 Mn procedures of botulinum toxin were done globally.  and in 2013, American Society for Dermatologic Surgery survey reported that 20% rise in the botulinum toxin procedures compared to 2012.There is an abundance of dermatology service providers in low-income countries such as India, Thailand, Malaysia, and Vietnam who tend to prescribe chemical peels and various creams and lotions as the best treatment options for facial rejuvenation. However, in contrast to this, in economically affluent countries such as U.S., U.K., UAE and Japan, the use of only approved Botulinum type-A neurotoxins is seen and in such countries, close to 50% procedures are done using Botulinum type-A injections. Hence, easier availability of products and affordability is set to increase the demand for combination therapy for enhanced results and is therefore set to boost the global aesthetics combination therapy market.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-combination-aesthetics-market/#ulp-14mlyhjMGhVjZqa3

 

 

On the basis of region presence, combination therapies in aesthetics market is segmented into five key regions: North America, Latin America, Europe, Asia pacific, and Middle East and Africa. North America and Europe are the biggest markets for the combination therapies in aesthetics market. North America market is expected to continue to dominate over the next few years due to higher number of U.S. FDA approvals for botulinum products in the region. However, it is harder to get Health Canada approvals. Asia-Pacific market is comparatively smaller and less penetrated than other regional markets. However, it is one the fastest growing market due to rising patient awareness for various therapeutic options and increase in accessibility to these procedures. Combination treatments such wrinkle lifting plus volume restoring are gaining popularity in this region. Healthy economic growth and disposable income levels in Brunei, Cambodia, Indonesia, Laos, Malaysia, Philippines, Singapore, Thailand, and Vietnam contribute largely to increasing demand for facial injectable products.

 

Some of the key market players in the combination therapies in aesthetics market are Merz Pharma GmbH & Co. KGaA (Germany), Biopolymer GmbH &Co KG (Germany), Revance Therapeutics Inc. (U.S.), Mentor Worldwide LLC (U.S.), Alma Lasers (Israel), Anika Therapeutics.Inc. (U.S.), Contura International A/S (Denmark), Cynosure. Inc. (U.S.), and GaldermaS.A. (Nestle) (Switzerland)

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-combination-aesthetics-market/

 

more...
No comment yet.
Scooped by rao
Scoop.it!

Global Surgical Devices Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Surgical devices refer to the medical devices used to cutting, dilating, grasping, holding, and fulgurate the body tissues during the surgical procedures. Some surgical devices are designed for general use in surgery, while others are designed for a specific procedure or surgery. Surgical devices are used for various surgical procedures such as reconstructive and plastic surgeries and wound closures. These are commonly used in various therapeutic areas such as urology, neurology, cardiovascular medicine, orthopaedics, obstetrics, and gynaecology, etc. Over time, many different kinds of surgical instruments and tools have been invented. Due to technological advancements majority of the surgical devices has computerized. The surgical devices categorized into different tools like powered devices, mechanical cutters, graspers, retractors, distractors, tubes and suction tips,  measurement tools, specula or dilators, tyndallers and among others

 Global Market Outline: Surgical Devices Market

 The global surgical devices market is expected to grow at a significant CAGR due to increase in the global population, and rise in the prevalence of various chronic diseases such as cancer, diabetes etc. Rise in demand for surgical tools due to increase in surgical procedures, increase in healthcare expenditure, increase in demand for plastic and reconstructive surgery, and rise in technological development leading to product innovations are the major factors fuel the growth of surgical devices market over the forecast period. Moreover, the favourable government policies for the manufacturing of surgical devices, the presence of numerous risk factors, such as hypertension, smoking, obesity, and diabetes, has led to the high prevalence of cardiovascular diseases and using of robotic systems might fuel the global surgical devices market over the forecast period. However, stringent government regulations, price competition in the industry and lack of proper reimbursement for surgical equipment may hamper the surgical devices market growth over the forecast period. Similarly, a rise in preference for advanced wound closure materials like fibrin sealants, implementation of acts like Patient Protection and Affordable Care Act (PPACA) in U.S., and Side effects with the products that lead to product recalls might hinder the growth of global surgical devices market.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-surgical-devices-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

Surgical devices market segmented on the basis of product type, application, and end user

 

Based on product-type surgical devices market has been segmented into the following:

  • Surgical Sutures and Staples
    • Surgical Sutures
    • Surgical Staples
  • Handheld Surgical equipment
    • Forceps and Spatulas
    • Retractors
    • Dilators
    • Graspers
    • Auxiliary Instruments
      • Clamps
      • Cannulas
      • Closure Devices
    • Cutter Instruments
      • Trocars
      • Lancets
      • Scissors
    • Others
  • Electrosurgical Devices

 

Based on the application surgical devices market has been segmented into the following:

  • Neurosurgery
  • Plastic and Reconstructive Surgeries
  • Wound Closure
  • Obstetrics and Gynaecology
  • Urology
  • Microvascular
  • Thoracic Surgery
  • Cardiovascular
  • Orthopaedic Surgery
  • Laparoscopy
  • Others

 

Based on end-user surgical devices market has been segmented into the following:

  • Hospitals
  • Clinics
  • Ambulatory surgical centers

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-surgical-devices-market/#ulp-c654SbFYO64MsOhu

 

 

Geographically, surgical devices market is in a flourishing stage with several local, and international players operating in the surgical devices market. Increase in the prevalence of chronic diseases such as neurological disorders (according to World Federation of Neurology statistics, 12 in every 100 patients die due to neurological disorders), and rise in the number of road accidents (according to Association for Safe International Road Travel, nearly 2.35 million people are injured every year due to road accidents) has led to the increase in  the demand for surgical devices. Launching of new products is the popular strategy followed by various medical devices companies in the global surgical equipment market, which has helped the manufacturers to gain substantial market share. For instance, in October 2013, Zimmer had launched three products for minimally invasive surgery, namely Viewline Retractor System, Tube Retraction System and Posterior Instrument Set which are used in microdiscectomy procedures. Similarly, innovation of modern technologies like minimally invasive surgery instruments, and robotic and power assisted equipment are the key factors fueling the growth of surgical devices market. For instance, in 2011, Intuitive Surgical, Inc., has developed the da Vinci Surgical System provided a breakthrough platform for the robotic-assisted surgeries.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-surgical-devices-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, the surgical devices market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Middle East & Africa, and Latin America. North America dominates the surgical devices market owing to rise in a number aging population, increase in the prevalence of chronic diseases in U.S. such as cancer, neurological disorders, and diabetes etc. The innovation of novel technologies and reimbursement scenario might boost the surgical devices market in North America. However, Europe holds a significant share in surgical devices market owing to the favourable regulatory framework, change in lifestyle, and increase in disposable income among consumers. Moreover, Asia-pacific surgical devices market is expected to substantial growth over forecasting period owing to increase in the medical tourism in Asian countries, rise in unmet healthcare needs, growing healthcare infrastructure in Asia Pacific region.

 

Some of the players in surgical devices market are Medtronic (U.S.), Stryker Corporation (U.S.), Johnson & Johnson Services Inc., (U.S.), NuVasive, Inc. (U.S.),  Conmed Corporation (U.S.), Alcon company (a division of Novartis) (Switzerland.), Smith & Nephew (U.K.) , Zimmer Inc. (U.S.), Boston Scientific Corporation (U.S.), B. Braun Melsungen AG (Germany), KLS Martin Group (U.S.), and Integra LifeSciences Corporation (U.S.) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-surgical-devices-market/

more...
No comment yet.
Scooped by rao
Scoop.it!

Global Hepatitis B Virus Testing Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Hepatitis B is a liver disease caused by the Hepatitis B virus (HBV). Hepatitis B viral infection ranges can form mild infection which last few weeks and a chronic infection that may lead to liver disorders and even death. Hepatitis B is one of the global health problem. Hepatitis B can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer. The virus is transmitted through contact with the blood or other body fluids of an infected person. According to World Health Organization, 257 Mn people are living with hepatitis B virus infection worldwide and in 2015, 887 000 hepatitis B resulted deaths.

 Increase in liver cancer cases, growing aging population, healthcare spending and urbanization. leading to better monitoring and screening procedures. In addition, government initiatives in growing awareness in public, increase in R&D spending by companies and growing demand for bio marker tests due to its accuracy expected to boost the hepatitis B virus testing market during the forecast period. However, factors such as lack of awareness in developing countries, stringent regulatory rules, rigid competition and high cost of testing are expected to hamper the hepatitis B virus testing market over the forecast period.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-b-virus-testing-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

The global hepatitis B testing market is classified on the basis of test type, technique end use, and geography.

 

Based on test type, the global hepatitis B diagnostic test market is segmented into the following:

  • Hepatitis B surface antigen test (HBsAg)
  • Anti-hepatitis B surface antibody test
  • Hepatitis B core antigen test (HBcAb)
  • Anti-hepatitis B core antibody test
  • HBV DNA test
  • Others

 

Based on techniques, the global hepatitis B diagnostic test market is segmented into the following:

  • PCR
  • Radioimmunoassay (RIA)
  • Enzyme-linked immunosorbent assay (ELISA)
  • Others

 

Based on end-user type, the global hepatitis B diagnostic test market is segmented into the following:

  • Hospitals
  • Diagnostic centers
  • Clinics

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-b-virus-testing-market/#ulp-c654SbFYO64MsOhu

 

 

Currently, more than 13 immunoassays are available to diagnose hepatitis B virus at an early stage. They can also be used to distinguish acute and chronic hepatitis B infections. Many governments in the European countries and the US made it mandatory for the people to go through the screening and proper monitoring since hepatitis B takes the time to develop and is not easily recognizable. There are some curative therapies available but they are not very efficient. It is expected that many innovative therapies which have shown positive results in trials will occupy the market in the coming years. Many companies have products related to hepatitis B in their pipeline. Vendors are developing devices and systems that help integrate laboratory applications. For instance, in 2010 the COBAS 6000 modular platform by Roche Diagnostics offers optimum efficiency and consolidation in medium- and high-volume laboratories.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-b-virus-testing-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, hepatitis B testing market has been segmented into North America, Europe, Latin America, Asia-Pacific, and The Middle East & Africa. North America dominated the hepatitis B therapeutics market owing to the high awareness levels, availability of improved infrastructure, and favourable government initiatives relating to the promotion of hepatitis B therapeutics. Europe is the second largest market for hepatitis B therapeutics driven by rising geriatric population, high rates of chronic infections in Central and Eastern Europe e European Centre for Disease Prevention and Control (ECDC) estimates an overall hepatitis B incidence of 1.49 per 100 000, prevalence of hepatitis B is the highest in Middle East & Africa where adult population is chronically infected. According to World Health Organization (WHO), 2% to 5% of population is affected with hepatitis B virus in Asia Pacific region. And most people die with liver diseases.

 

Some of the players hepatitis B testing market are Onsite Lab Holding AG (MedMira Inc.) (Switzerland), F. Hoffmann-La Roche (Switzerland), Abbott Laboratories (USA), Siemens AG (Siemens Healthcare GmbH) (Germany), Fisher Bioblock Bolding (Thermo Fisher Scientific) (France), Innovita biological technology Co. Ltd. (China), General Biologicals Corporation (Taiwan), Nantong Diagnos Biotechnology Co. Ltd. (China), Blue Cross Bio-Medical (China) Co. Ltd., BioGenex (U.S.), and Abnova Corporation (U.S.), among others.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-hepatitis-b-virus-testing-market/

more...
No comment yet.
Scooped by rao
Scoop.it!

Global Companion Diagnostic Devices Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

 

Companion diagnostics are medical devices, often an in-vitro device and provides the information that essential for safe and effective use of the corresponding drug or biotechnology product. Companion diagnostics are often developed along with drugs to aid in selecting or excluding the patient groups for the treatment with particular drug on basis of their biological characters. Companion diagnostics are developed based on biomarkers technology to predict response or severe toxicity of the drugs or biotechnological compounds. Companion diagnostics are majorly used in oncology area.

 

Some of the factors like improved efficacy and safety profiles of drugs, Accelerated drug regulatory approvals, reduced healthcare expenditure and drug development costs, increasing partnerships between market players, government organizations and other research firms over the use of co diagnostics, emergence of new pharmaceuticals and diagnostics are driving the growth of the global companion diagnostics market. However, due to the regulatory uncertainty, complex clinical trial procedures and intellectual property issues in certain areas are the few issues which are restraining the growth of the global companion diagnostics market.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-companion-diagnostic-devices-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

Global companion diagnostic tests are segmented on the basis of application, technology, end user and geographical region.

 

Based on the application, global companion diagnostic tests are segmented as:

  • Breast Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Urology
  • Melanoma
  • Gastric Cancer
  • Others

 

Based on the type, global companion diagnostic tests are segmented as:

  • Screening and Detection Tests
  • Prognosis Tests
  • Theranostics Tests
  • Monitoring Tests
  • Recurrence Tests

 

Based on the end-user, global companion diagnostic tests are segmented as:

  • Hospitals
  • Diagnostic Centres
  • Others

 

To view TOC of this report is available upon request @

 https://www.precisionbusinessinsights.com/market-reports/global-companion-diagnostic-devices-market/#ulp-c654SbFYO64MsOhu

 

 

The global companion diagnostic devices market is highly fragmented due to the presence of several established large and small suppliers. The competition in the market will intensify during the forecast period as vendors adopt strategies like M&A to develop new technologies. Product approval and launch will also help to increase the volume of available diagnostic devices in the market. In addition, the vendors also work on differentiating their products based on quality, the accuracy of results, and other value added services as it will help them to gain a competitive edge over their peers.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-companion-diagnostic-devices-market/#ulp-14mlyhjMGhVjZqa3

 

 

Geographically, companion diagnostic devices market is segmented into five regions: North America, Europe, Latin America, Asia-Pacific and Middle East & Africa. North America expected to be major market for companion diagnostics owing to growth innovative technologies in biomarkers, increase in R&D investment in the region.  Asia-Pacific and Europe are expected to grow at a significant rate owing to large patent and consumer base, increasing government initiatives developing healthcare infrastructure, and growing disposable income.

 

Some of the players in companion diagnostic devices market are F. Hoffmann-La Roche Ltd.(Switzerland), Qiagen Ltd. (Germany), ARUP Laboratories (U.S.), Abbott Laboratories (U.S.), Biogenex Laboratories, Inc. (USA), Thermo Fisher Scientific (U.S), Ventana Medical Systems Inc. (U.S), Myriad Genetics Inc. (U.S), and Danaher (U.S) and others.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-companion-diagnostic-devices-market/

 

more...
No comment yet.